Search

Sarcomas are mesenchymal tumors of soft tissues and bone that are usually fatal when they progress beyond local control. Dating back to the 19th century, attempts have been made to treat sarcomas with immunotherapy. These attempts were either with highly toxic Coleys toxins or less potent vaccine therapies as well as unsuccessful trials with interferons. Interestingly, osteosarcoma was one of the first cancers to get regulatory approval with the immunotherapeutic agent mifamurtide L-MTPPE and is currently approved in Europe for use in combination with adjuvant chemotherapy. With the advent of modern immune checkpoint inhibitors, several trials have since been completed and further are ongoing to test the safety and efficacy of immunotherapy in sarcomas. Owing to the significant heterogeneity of sarcomas, as well as our still somewhat limited understanding on the biology behind this group of diseases, the results of these trials have been a bit of a hit-and-miss. During this talk, the successes and failures of developing immunotherapeutics in sarcomas will be highlighted, and whether immunotherapy truly holds the key to the future of deadly group of diseases will be discussed. [ABSTRACT FROM AUTHOR]